Pharmaceutical compositions for direct systemic introduction
The invention relates to pharmaceutical compositions for direct systemic introduction, are also known as DSI pharmaceutical compositions, for used as human veterinary pharmaceutical compositions. In one embodiment, the invention relates to a pharmaceutical composition for direct system introduction comprising bovine gelatin, mannitol, an optional surfactant, an optional flavorant, and an active pharmaceutical ingredient. A DSI pharmaceutical composition of the invention has a disintegration time of 7 seconds or less in deionized water maintained at 37.0° C.±0.5° C. The invention also relates to a method of delivering an active pharmaceutical ingredient to an animal comprising the step of placing a DSI pharmaceutical composition of the invention into a mucosal cavity of an animal to be treated with the active pharmaceutical ingredient and to the corresponding methods of treatment.
1. A pharmaceutical composition for direct system introduction comprising:
about 10-17 dry mass % bovine gelatin,
about 10-17 dry mass % mannitol,
about 0-1 dry mass % of a surfactant,
about 0-0.5 dry mass % of a flavorant, and
about 65-80 dry mass % of a proton pump inhibitor.
2. A pharmaceutical composition of claim 1 comprising:
about 10-13 dry mass % bovine gelatin,
about 12-15 dry mass % mannitol, and
about 0.1-0.3 dry mass % of a surfactant.
3. A pharmaceutical composition of claim 1 wherein the proton pump inhibitor is omeprazole.
4. A pharmaceutical composition of claim 1 , having a disintegration time of 7 seconds or less in deionized water maintained at 37.0° C. ±0.5° C.
5. A pharmaceutical composition of claim 1 , having a disintegration time of 4 seconds or less in deionized water maintained at 37.0° C. ±0.5° C.
6. A method of delivering an active pharmaceutical ingredient to an animal via the animal's non-keratinous tissues comprising the step of placing a pharmaceutical composition of claim 1 into a mucosal cavity of an animal to be treated with the active pharmaceutical ingredient.
7. A method of claim 6 , wherein the animal is equine.
8. A method of claim 6 , wherein the animal is human.
9. A method of claim 6 , wherein the mucosal cavity is selected from an oral cavity, an anal cavity, a vaginal cavity, a nasal cavity, a gingival mucosa, a lingual mucosa, a palatal mucosa, a pharyngeal mucosa, a sublingual mucosa, and a non-gastric mucosa.
10. A method of claim 9 , wherein the proton pump inhibitor is omeprazole.
11. A method of claim 6 , wherein the mucosal cavity is an oral cavity.
12. A method of claim 11 , wherein the proton pump inhibitor is omeprazole.
13. A pharmaceutical composition of claim 1 , wherein the proton pump inhibitor is esomeprazole.
14. A method of claim 9 , wherein the proton pump inhibitor is esomeprazole.
15. A method of claim 11 , wherein the proton pump inhibitor is esomeprazole.